Adlai Nortye (ANL) Cash & Equivalents (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Cash & Equivalents of $8.1 million for Q4 2025, down 86.77% year-over-year from $60.9 million in Q4 2024, and down 81.75% quarter-over-quarter from $44.1 million in Q2 2025.
Analysis
Adlai Nortye (ANL) Cash & Equivalents (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Cash & Equivalents for 4 consecutive years, with $8.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash & Equivalents fell 86.77% year-over-year to $8.1 million; the TTM figure through Dec 2025 stood at $8.1 million (down 86.77% YoY), while the FY2025 annual figure was $8.1 million, down 86.77% from the prior year.
- Cash & Equivalents fell to $8.1 million in Q4 2025 per ANL's latest filing, from $44.1 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $98.0 million in Q2 2024 and bottomed at $8.1 million in Q4 2025.
- Historically, Cash & Equivalents has averaged $57.6 million across 4 years, with a median of $52.5 million in 2024.
- Annual changes were most pronounced in 2023 — Cash & Equivalents surged 113.98% — and 2025, when it plunged 86.77%.
- Adlai Nortye's Cash & Equivalents stood at $42.8 million in 2022, then jumped by 113.98% to $91.5 million in 2023, then plunged by 33.43% to $60.9 million in 2024, then slumped by 86.77% to $8.1 million in 2025.
- Business Quant data shows ANL's Cash & Equivalents at $8.1 million in Q4 2025, $44.1 million in Q2 2025, and $60.9 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | 132.59 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 132.59 Mn |
| Dec 31, 2025 | 8.06 Mn |
| Jun 30, 2025 | 44.14 Mn |
| Dec 31, 2024 | 60.90 Mn |
| Jun 30, 2024 | 97.98 Mn |
| Dec 31, 2023 | 91.49 Mn |
| Dec 31, 2022 | 42.76 Mn |